questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Antigènes B7
Antigène CD274
Antigène CD274 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Antigène CD274
Immunohistochimie
Cancer du poumon
Cancer du sein
Lymphocytes T
Système immunitaire
Symptômes
5
Immunosuppression
Infections
Maladies auto-immunes
Cellules T
Réponse immunitaire
Infections
Tests cliniques
Symptômes
Prévention
5
Prévention
Expression génique
Mode de vie sain
Système immunitaire
Détection précoce
Gestion du cancer
Habitudes alimentaires
Expression génique
Traitements
5
Inhibiteurs de PD-1
Pembrolizumab
Thérapies immunologiques
Réponse immunitaire
Thérapie génique
Expression génique
Effets secondaires
Réactions auto-immunes
Efficacité des traitements
Profil immunitaire
Complications
5
Immunosuppression
Progression tumorale
Maladies auto-immunes
Infections chroniques
Résistance aux traitements
Thérapies immunologiques
Survie des patients
Pronostic
Complications
Traitement approprié
Facteurs de risque
5
Facteurs de risque
Antécédents de cancer
Tabagisme
Cancer du poumon
Obésité
Expression génique
Infections virales
Cellules immunitaires
Stress chronique
Réponse immunitaire
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigène CD274 : Questions médicales les plus fréquentes",
"headline": "Antigène CD274 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigène CD274 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-16",
"dateModified": "2025-02-10",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigène CD274"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antigènes B7",
"url": "https://questionsmedicales.fr/mesh/D060887",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes B7",
"code": {
"@type": "MedicalCode",
"code": "D060887",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.168"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigène CD274",
"alternateName": "B7-H1 Antigen",
"code": {
"@type": "MedicalCode",
"code": "D060890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Soldano Ferrone",
"url": "https://questionsmedicales.fr/author/Soldano%20Ferrone",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Haidong Dong",
"url": "https://questionsmedicales.fr/author/Haidong%20Dong",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Mayo Clinic, Rochester, MN, USA."
}
},
{
"@type": "Person",
"name": "Hongwei Du",
"url": "https://questionsmedicales.fr/author/Hongwei%20Du",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA."
}
},
{
"@type": "Person",
"name": "Barbara Savoldo",
"url": "https://questionsmedicales.fr/author/Barbara%20Savoldo",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA."
}
},
{
"@type": "Person",
"name": "Gianpietro Dotti",
"url": "https://questionsmedicales.fr/author/Gianpietro%20Dotti",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA. Electronic address: gdotti@med.unc.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Prostatic Urethral Length as a Predictor for Surgery in Benign Prostatic Hyperplasia.",
"datePublished": "2023-03-10",
"url": "https://questionsmedicales.fr/article/36974872",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.33314/jnhrc.v20i3.4613"
}
},
{
"@type": "ScholarlyArticle",
"name": "Is there a best timing for benign prostatic hyperplasia surgery?",
"datePublished": "2024-02-05",
"url": "https://questionsmedicales.fr/article/38717461",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.fjurol.2024.102574"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer.",
"datePublished": "2022-07-05",
"url": "https://questionsmedicales.fr/article/35865814",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fcimb.2022.894777"
}
},
{
"@type": "ScholarlyArticle",
"name": "Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.",
"datePublished": "2024-10-07",
"url": "https://questionsmedicales.fr/article/39373947",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11934-024-01235-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostatic arterial embolisation for men with benign prostatic hyperplasia: a Cochrane review.",
"datePublished": "2022-07-13",
"url": "https://questionsmedicales.fr/article/35696302",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bju.15823"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Antigènes B7",
"item": "https://questionsmedicales.fr/mesh/D060887"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antigène CD274",
"item": "https://questionsmedicales.fr/mesh/D060890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigène CD274 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigène CD274",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigène CD274",
"description": "Comment diagnostiquer une expression anormale de CD274 ?\nQuels tests sanguins sont utilisés pour CD274 ?\nCD274 est-il associé à des biomarqueurs spécifiques ?\nQuels types de cancers montrent une surexpression de CD274 ?\nComment évaluer l'impact de CD274 sur le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Prostatic+Hyperplasia#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigène CD274",
"description": "Quels symptômes sont liés à une surexpression de CD274 ?\nCD274 influence-t-il les symptômes des maladies auto-immunes ?\nY a-t-il des symptômes spécifiques au cancer liés à CD274 ?\nComment CD274 affecte-t-il la réponse aux infections ?\nLes symptômes de CD274 sont-ils visibles cliniquement ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Prostatic+Hyperplasia#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigène CD274",
"description": "Peut-on prévenir l'expression de CD274 ?\nComment un mode de vie sain influence-t-il CD274 ?\nY a-t-il des vaccins ciblant CD274 ?\nLa détection précoce des cancers aide-t-elle à gérer CD274 ?\nLes habitudes alimentaires influencent-elles CD274 ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Prostatic+Hyperplasia#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigène CD274",
"description": "Quels traitements ciblent CD274 ?\nComment les thérapies immunologiques agissent-elles sur CD274 ?\nCD274 peut-il être une cible pour la thérapie génique ?\nQuels effets secondaires sont associés aux traitements ciblant CD274 ?\nLes traitements de CD274 sont-ils efficaces pour tous les cancers ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Prostatic+Hyperplasia#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigène CD274",
"description": "Quelles complications sont liées à une surexpression de CD274 ?\nCD274 peut-il aggraver des maladies existantes ?\nY a-t-il des risques de résistance aux traitements avec CD274 ?\nComment CD274 influence-t-il la survie des patients ?\nLes complications de CD274 sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Prostatic+Hyperplasia#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigène CD274",
"description": "Quels facteurs augmentent le risque d'expression de CD274 ?\nLe tabagisme influence-t-il CD274 ?\nY a-t-il un lien entre l'obésité et CD274 ?\nLes infections virales affectent-elles CD274 ?\nLe stress chronique influence-t-il CD274 ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Prostatic+Hyperplasia#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une expression anormale de CD274 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests immunohistochimiques peuvent être utilisés pour détecter CD274 dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour CD274 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dosages de cytokines et des tests de surface cellulaire peuvent évaluer CD274."
}
},
{
"@type": "Question",
"name": "CD274 est-il associé à des biomarqueurs spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 est souvent associé à des biomarqueurs de cancer comme PD-1."
}
},
{
"@type": "Question",
"name": "Quels types de cancers montrent une surexpression de CD274 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cancers du poumon, du sein et de la vessie montrent souvent une surexpression de CD274."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'impact de CD274 sur le système immunitaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études fonctionnelles sur les lymphocytes T peuvent évaluer l'impact de CD274."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une surexpression de CD274 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surexpression de CD274 peut entraîner une immunosuppression et des infections fréquentes."
}
},
{
"@type": "Question",
"name": "CD274 influence-t-il les symptômes des maladies auto-immunes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 peut exacerber les symptômes des maladies auto-immunes en inhibant les cellules T."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au cancer liés à CD274 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure la fatigue, la perte de poids et des douleurs localisées."
}
},
{
"@type": "Question",
"name": "Comment CD274 affecte-t-il la réponse aux infections ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une expression élevée de CD274 peut réduire l'efficacité de la réponse immunitaire aux infections."
}
},
{
"@type": "Question",
"name": "Les symptômes de CD274 sont-ils visibles cliniquement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, CD274 n'a pas de symptômes visibles, mais son impact est observé par des tests."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'expression de CD274 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode spécifique pour prévenir l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Comment un mode de vie sain influence-t-il CD274 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut renforcer le système immunitaire, potentiellement régulant CD274."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins ciblant CD274 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiquement ciblant CD274."
}
},
{
"@type": "Question",
"name": "La détection précoce des cancers aide-t-elle à gérer CD274 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la détection précoce peut permettre une intervention rapide sur l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles CD274 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que l'alimentation peut moduler l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent CD274 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de PD-1 et PD-L1, comme le pembrolizumab, ciblent CD274."
}
},
{
"@type": "Question",
"name": "Comment les thérapies immunologiques agissent-elles sur CD274 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles bloquent l'interaction entre CD274 et PD-1, stimulant ainsi la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "CD274 peut-il être une cible pour la thérapie génique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches explorent la thérapie génique pour moduler l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires sont associés aux traitements ciblant CD274 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions auto-immunes et des inflammations."
}
},
{
"@type": "Question",
"name": "Les traitements de CD274 sont-ils efficaces pour tous les cancers ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'efficacité varie selon le type de cancer et le profil immunitaire du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à une surexpression de CD274 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent une immunosuppression accrue et une progression tumorale."
}
},
{
"@type": "Question",
"name": "CD274 peut-il aggraver des maladies existantes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 peut aggraver des maladies auto-immunes et des infections chroniques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de résistance aux traitements avec CD274 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la surexpression de CD274 peut entraîner une résistance aux thérapies immunologiques."
}
},
{
"@type": "Question",
"name": "Comment CD274 influence-t-il la survie des patients ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une expression élevée de CD274 est souvent associée à un pronostic défavorable dans le cancer."
}
},
{
"@type": "Question",
"name": "Les complications de CD274 sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'expression de CD274 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents de cancer, des infections chroniques et l'âge."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il CD274 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter l'expression de CD274, surtout dans le cancer du poumon."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien entre l'obésité et CD274 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que l'obésité peut être associée à une expression accrue de CD274."
}
},
{
"@type": "Question",
"name": "Les infections virales affectent-elles CD274 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections virales peuvent induire l'expression de CD274 dans les cellules immunitaires."
}
},
{
"@type": "Question",
"name": "Le stress chronique influence-t-il CD274 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut moduler l'expression de CD274, affectant la réponse immunitaire."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 10/02/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Department of Urology, Mayo Clinic, Rochester, MN, USA.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA. Electronic address: gdotti@med.unc.edu.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Department of Neurosurgery West China Hospital West China Medical School Sichuan University Chengdu China.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
State Key Laboratory of Biotherapy West China Hospital West China Medical School Sichuan University Chengdu China.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Department of Neurosurgery West China Hospital West China Medical School Sichuan University Chengdu China.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, SZ, China.
Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, SZ, China.
SuZhou Bright Scistar Antibody Biotech co., Ltd, 303-305, Bldg 15, NO.8, Jinfeng Road, Suzhou, SZ, China.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Medical University of Graz, Graz, Austria.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Medical University of Graz, Graz, Austria.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai, 200080, China.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Mayo Clinic, Rochester, MN, USA.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Immunology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210, USA. Electronic address: songguozheng2013@yahoo.com.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
National Animal Disease Center, USDA-ARS, Ames, Iowa, USA.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
National Animal Disease Center, USDA-ARS, Ames, Iowa, USA.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
National Animal Disease Center, USDA-ARS, Ames, Iowa, USA.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Royal Veterinary Collegegrid.20931.39, London, United Kingdom.
OIE/FAO International Reference Laboratory for Avian Influenza, Swine Influenza and Newcastle Disease, Animal and Plant Health Agency (APHA), Weybridge, Addlestone, Surrey, United Kingdom.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
National Animal Disease Center, USDA-ARS, Ames, Iowa, USA.
Publications dans "Antigène CD274" :
Benign prostatic hyperplasia is associated with structural and morphological changes including elongation of prostatic urethral length. The aim of our study was to assess whether prostatic urethral le...
This prospective observational study was conducted over a 12-months duration. All the patients who presented with lower urinary tract symptoms secondary to benign prostatic hyperplasia were evaluated ...
A total of 153 patients were included in the study. Eighty-three (54.2%) patients underwent surgery during the study period. Prostate volume, intravesical prostatic protrusion, post-void residual volu...
BPH patients with longer PUL may require surgical management. PUL measured by TRUS may be a predicting factor for the need of surgery in BPH Keywords: Benign prostatic hyperplasia; lower urinary tract...
Treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH) has shifted over the last decades, with medical therapy becoming the primary treatment modality while sur...
A literature search was conducted on Pub-Med/MEDLINE database to identify reports published from January 1990 until January 2022 by combining the following MeSH terms: "Lower Urinary Tract Symptoms"; ...
The "pro early surgery" highlighted the superior efficacy and cost-effectiveness of surgery over medical treatment for BPH, as well as the possibility of worse postoperative outcomes for delayed surgi...
Clinical trials comparing the outcomes for prolonged medical therapy versus early surgical treatment could determine which approach is more beneficial in the long-term in context of the aging populati...
Apart from other risk factors, chronic inflammation is also associated with the onset of Prostate Cancer (PCa), wherein pathogen infection and tissue microbiome dysbiosis are known to play a major rol...
The prevalence of benign prostatic hyperplasia (BPH) is rising, however, current treatment options present severe complications and limit patient's quality of life. Accordingly, advancements in prosta...
The dual dilation and paxlitaxel eluting Optilume BPH Catheter System enhances promise in catheter-based treatments, providing the longest sustained increase in max urinary flow rate and decrease in p...
To assess the effects of prostatic arterial embolisation (PAE) compared to other procedures for treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH)....
We included randomised controlled trials (RCTs), as well as non-randomised studies (NRSs) enrolling men with BPH undergoing PAE vs other surgical interventions via a comprehensive search up until 8 No...
We found data to inform two comparisons: PAE vs transurethral resection of prostate (TURP; six RCTs and two NRSs), and PAE vs sham (one RCT). This abstract focuses on the primary outcomes in a compari...
Compared to TURP, the impact on urological symptoms and QoL improvement as perceived by patients appears to be similar. This review did reveal major uncertainty as to how major adverse events compare....
Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over the age of 50 years. An association between the prostate specific antigen (PSA), International Pro...
To determine the correlation between the PSA, IPSS and PV in men of African descent....
This was a cross sectional analysis involving 92 patients diagnosed as having symptomatic BPH at the Ho Teaching Hospital....
The data were collected using standardised questionnaires. The IPSS determined urinary symptom severity. The PV was determined using a transabdominal ultrasound machine. Serum PSA was retrieved from t...
The mean PV was 61.04 cm3 ± 21.95 cm3, the mean PSA was 4.21 ng/mL ± 3.85 ng/mL, and mean IPSS of 21.59 ± 3.78. The Pearson's correlation between PV and PSA was 0.283 (p = 0.01), between PV and IPSS w...
This study showed that serum PSA has a positive correlation with PV. However, IPSS had no significant association with PSA or PV in patients with BPH.Contribution: This study provides insights into th...
It is a known fact that the role of microRNAs (miRNA) has a very important place in cancer development and progression. miRNAs target a significant part of pathways as well as genes. This study aimed ...
Peripheral blood mononuclear cells (PBMCs) and tissue samples were collected from prostate cancer (PCa) (n: 20) and benign prostatic hyperplasia (BPH) (n: 20) patients. Total RNA isolation was perform...
In tissue samples, 37 different expressed miRNAs were identified in PCa patients compared to BPH patients. In PBMCs samples, 27 different expressed miRNAs were identified in PCa patients compared to b...
Our results suggested that determined common hsa-miR-494-3p, hsa-miR-3128, hsa-miR-8084 and their target HIF1A, AVRP1A, NHS, INSL4 may play a crucial role in therapeutic and early diagnostic strategie...
To compare the cost effectiveness of prostatic artery embolization (PAE) with that of transurethral resection of the prostate (TURP) for the treatment of medically refractory benign prostatic hyperpla...
A cost-effectiveness analysis with Markov modeling was performed, comparing the clinical course after PAE with that after TURP for 3 years. Probabilities were obtained from the available literature, a...
Base case calculation showed comparable outcomes (PAE, 2.845 QALY; TURP, 2.854 QALY), with a cost difference of $3,104 (PAE, $2,934; TURP, $6,038). The incremental cost-effectiveness ratio was $360,24...
PAE is a cost-effective strategy to treat medically refractory BPH, resulting in comparable health benefits at a lower cost than that of TURP even when accounting for extreme alterations in adverse ev...
Autophagy is a cellular homeostatic mechanism characterized by cyclic degradation. It plays an essential role in maintaining cellular quality and survival by eliminating dysfunctional cellular compone...
Interventions for benign prostatic hyperplasia have evolved from transurethral resection of the prostate and simple prostatectomy to a myriad of office-based and operating-room procedures. The contemp...